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Abstract
Background: Human  α1-proteinase inhibitor (α1-PI), also known as antitrypsin, is the most
abundant serine protease inhibitor (serpin) in plasma. Its deficiency is associated with development
of progressive, ultimately fatal emphysema. Currently in the United States, α1-PI is available for
replacement therapy as an FDA licensed plasma-derived (pd) product. However, the plasma source
itself is limited; moreover, even with efficient viral inactivation steps used in manufacture of plasma
products, the risk of contamination from emerging viruses may still exist. Therefore, recombinant
α1-PI (r-α1-PI) could provide an attractive alternative. Although r-α1-PI has been produced in
several hosts, protein stability in vitro and rapid clearance from the circulation have been major
issues, primarily due to absent or altered glycosylation.
Results:  We have explored the possibility of expressing the gene for human α1-PI in the
filamentous fungus Aspergillus niger (A. niger), a system reported to be capable of providing more
"mammalian-like" glycosylation patterns to secretable proteins than commonly used yeast hosts.
Our expression strategy was based on fusion of α1-PI with a strongly expressed, secreted leader
protein (glucoamylase G2), separated by dibasic processing site (N-V-I-S-K-R) that provides in vivo
cleavage. SDS-PAGE, Western blot, ELISA, and α1-PI activity assays enabled us to select the
transformant(s) secreting a biologically active glycosylated r-α1-PI with yields of up to 12 mg/L.
Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) analysis further
confirmed that molecular mass of the r-α1-PI was similar to that of the pd-α1-PI. In vitro stability of
the r-α1-PI from A. niger was tested in comparison with pd-α1-PI reference and non-glycosylated
human r-α1-PI from E. coli.
Conclusion: We examined the suitability of the filamentous fungus A. niger for the expression of
the human gene for α1-PI, a medium size glycoprotein of high therapeutic value. The heterologous
expression of the human gene for α1-PI in A. niger was successfully achieved to produce the
secreted mature human r-α1-PI in A. niger as a biologically active glycosylated protein with improved
stability and with yields of up to 12 mg/L in shake-flask growth.
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Background
Human  α1-PI is a well-characterized serpin (for recent
reviews see [1-4]). Its best known physiological role is the
inhibition of neutrophil elastase in the lungs. α1-PI is an
abundant protease inhibitor in human plasma with a con-
centration range from 1.04 to 2.76 g/L in healthy individ-
uals and with a half-life of 4–5 days in circulation [5-7].
As a result of a single mutation, α1-PI (Z-form) undergoes
polymerization and accumulates in the liver, causing a
deficiency of α1-PI in the blood that may result in progres-
sive, ultimately fatal, emphysema [7].
α1-PI is a ~51 kDa single-chain glycoprotein (394 amino
acid residues, 12% carbohydrates). It has a typical serpin
secondary structure, featuring 9 α-helices, 3 β-sheets and
a reactive center loop that is exposed for interaction with
a target protease (e.g., review [3]).
Human pd-α1-PI is an FDA licensed product, used for
replacement therapy in patients with hereditary α1-PI
deficiency. However, the plasma source itself is limited;
moreover, even with testing source material for relevant
pathogenic viruses and robust viral clearance steps in the
manufacturing process of plasma products, a risk from
emerging and yet unknown viruses still remains. As an
alternative, and in addition to plasma-derived products,
the recombinant versions of α1-PI have been under inten-
sive investigation. Since the early 1980s, the human gene
for α1-PI has been expressed in various hosts, including E.
coli, yeasts, insect cells, CHO cells, as well as in transgenic
plants and animals (see recent review [8]).
We consider the filamentous fungi as a very attractive host
for production of human α1-PI and other proteins of bio-
medical interest. The filamentous fungi systems offer var-
ious post-translational modifications to proteins, includ-
ing glycosylation with the patterns that are more similar
to those of mammals than glycosylation provided by
common yeast hosts [9-11]. Although these systems have
been used for commercial production of enzymes, very
few human genes have been expressed in the filamentous
fungi [12,13]. Protein size, glycosylation and metastable
inhibitory nature of α1-PI represent the challenges in this
multi-step work in view of an exclusive therapeutic impor-
tance of this inhibitor. Moreover, it is worthwhile to men-
tion that multiple efforts of more than 20 years
development still did not bring any recombinant α1-PI
product to the market [8].
The most efficient strategy for expression of mammalian
heterologous genes in fungi is a production of the target
protein as a fusion protein linked to the C-terminus of a
highly expressed and well secreted native fungal protein
[14-16]. To release the target protein from the fusion chi-
mera, the in vivo cleavage is accomplished by introducing
the KEX2-type protease recognition site at the fusion junc-
tion [17-20].
In the present study we examined the suitability of fila-
mentous fungus A. niger for the expression of the human
gene for α1-PI. We successfully achieved heterologous
expression of the gene for α1-PI in A. niger to produce the
secreted mature human r-α1-PI as a biologically active gly-
cosylated protein with improved stability and with yields
of up to 12 mg/L in shake-flask growth.
Results
1. Expression vector, transformation and selection
The expression cassette of pAN56-1/α1-PI (Fig. 1) was
constructed as described in Methods. The correct insertion
of  α1-PI was verified by restriction digest and DNA
sequence analysis. Co-transformation of the protoplasts
of  A. niger strain D15#26 with pAN56-1/α1-PI and
pBLUE-AmdSPyrG (further referred as PyrG), followed by
the selection on uridine-deficient media enabled us to iso-
late the transformants containing the selection fragment.
Further screening for α1-PI production was performed by
direct detection of the secreted target protein in the super-
natants of shake-flask cultures.
2. Evaluation of proteolytic digestion by fungal proteases
Initially, the A. niger strain AB4-1 was used as the parental
host strain for transformation. However, during the
screening for r-α1-PI in shake-flask cultures we were una-
ble to detect the target protein in the supernatants from
the selected transformants. No band was seen on Western
blots at the electrophoretic mobility of the standard pd-
α1-PI, thus suggesting that either the transformants con-
tained only the PyrG plasmid, but not the expression vec-
tor, or that the target protein is not visible because of
proteolysis with native fungal proteases. This prompted us
to evaluate the possibility that α1-PI might be proteolyti-
cally digested under the conditions of shake-flask growth.
Given this reasoning, a protease-deficient host strain,
D15#26, was chosen that resulted in successfully pro-
duced amounts of r-α1-PI. (However, several other effects,
such as the efficiency of transcription from the sites of ran-
dom integration in different transformants, or differences
in the gene copy number between strains (not pursued in
this study) may also result in significant differences in
expression levels.)
Fig. 2 shows the results of the basic experiment conducted
with standard pd-α1-PI, which was spiked with superna-
tant from 5 days growth of parental A. niger strain AB4-1
transformed with PyrG plasmid only. Whereas standard
α1-PI in Tris buffer, pH 8.4 used as a control, was stable
during the time of the experiment (10 h) both at 4°C and
RT, the same amounts of α1-PI spiked with supernatant of
A. niger growth (naturally acidified during growth to pHMicrobial Cell Factories 2007, 6:34 http://www.microbialcellfactories.com/content/6/1/34
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of ~3.5–4.5) showed quick decay due to proteolysis that
proceeded significantly faster at room temperature (RT).
Two strategies were employed to minimize proteolysis in
this system. Proteolytic activity of native fungal proteases
is mainly neutralized by keeping the pH above 7. Sec-
ondly, a strain of A. niger more deficient in proteases, non-
acidifying mutant D15#26 was used (instead of AB4-1).
3. Analyses of the expression of α1-PI in A. niger
The results reported here utilize the D15#26 strain and pH
above 7.0, as indicated above. The supernatant samples
from the cultures were assayed by ELISA. In addition, to
minimize the possibility of false interpretation of the
ELISA results, SDS-PAGE and Western blot analysis were
used, since it was shown by us that the ELISA can detect
peptides derived from digestion of α1-PI [21]. Fig. 3 shows
a typical SDS-PAGE and complimentary Western blot for
the supernatant of the selected D15#26 transformant
taken after 96 hours of growth (lanes 3–5). Lanes 6–9 cor-
responds to another D15#26 selected transformant. The
yields estimated by ELISA and by Western blot were in
agreement indicating secretion of up to 12 mg/L of the tar-
get protein. The r-α1-PI was shown to be functionally
active (see below). No cytoplasmic accumulation was
detected in the control analysis of the A. niger cell extract.
4. Characterization of r-α1-PI from A. niger
Fig. 4 compares r-α1-PI from A. niger with standard pd-α1-
PI, enzymatically deglycosylated pd-α1-PI (de-pd-α1-PI),
and with r-α1-PI from E. coli. Unlike r-α1-PI in the soluble
protein fraction from E. coli (see SDS-PAGE in [21]), the
raw supernatant from A. niger has a relatively simple pro-
tein composition.
4.1. HPLC analyses
Size-exclusion (SE) HPLC data was used for the stability
evaluation of the r-α1-PI's. The fractions corresponding to
the α1-PI peak with a retention time of 21 min were col-
lected and stored on ice. It is noteworthy that the reten-
tion times of r-α1-PI's from A. niger and from E. coli are
essentially the same as that of pd-α1-PI (~21 minutes in
the conditions used). Fig. 5 demonstrates that whereas the
non-glycosylated r-α1-PI from E. coli (dashed trace)
undergoes rapid aggregation (as observed by accumula-
tion of the peak with a retention time of ~13 min corre-
sponding to polymerized α1-PI, gray trace), the
SDS-PAGE analyses of proteolytic digestion Figure 2
SDS-PAGE analyses of proteolytic digestion. 1 – protein lad-
der; 2 and 11 - α1-PI standard; 3 - α1-PI standard kept O/N at 
RT; 4 – Supernatant (S) from 5 days growth of A. niger AB4-1; 
5 - α1-PI + S (initial, pH 3.5) O/N, RT; 6 - α1-PI + S (initial, pH 
3.5) O/N, 4°C; 7 - α1-PI + S pH 7.3 kept O/N at RT; 8 - α1-PI 
+ S pH 7.3 kept O/N at 4°C; 9 - α1-PI + S pH 8.4 kept O/N 
at RT; 10 - α1-PI + S pH 8.4 kept O/N at 4°C. The initial con-
centration of α1-PI standard in all samples was 5.175 mg/mL.
Diagram of the fusion region between glucoamylase (GLA) and α1-PI coding region (A1-PI) within the pAN56-1 expression  vector showing the KEX2 cleavage sequence (see abbreviations in the text) Figure 1
Diagram of the fusion region between glucoamylase (GLA) and α1-PI coding region (A1-PI) within the pAN56-1 expression 
vector showing the KEX2 cleavage sequence (see abbreviations in the text).Microbial Cell Factories 2007, 6:34 http://www.microbialcellfactories.com/content/6/1/34
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SDS-PAGE and western blot (right panel) comparison of different α1-PI's: 1-protein ladder; 2 and 6 - pd-α1-PI standard; 3 -  deglycosylated pd-α1-PI; 4 - α1-PI from E. coli Figure 4
SDS-PAGE and Western blot (right panel) comparison of different α1-PI's: 1- protein ladder; 2 and 6 - pd-α1-PI standard; 3 - 
deglycosylated pd-α1-PI; 4 - α1-PI from E. coli (eluted from TALON beads); 5 - r-α1-PI in the supernatant from A. niger D15#26.
SDS-PAGE and western blot (right panel) analysis of α1-PI expression in A. niger D15#26 Figure 3
SDS-PAGE and Western blot (right panel) analysis of α1-PI expression in A. niger D15#26. 1-protein ladder, 2 and 10 - pd-α1-PI 
standard, 3–5 - supernatant from growth of the transformant #1 (30, 20, and 10 μL respectively), 6 – supernatant from growth 
of PYRG-transformant, 7–9 - supernatant from growth of the transformatant #2 (the 30, 20, and 10 μL respectively).
1  2   3   4   5   6   7  8   9  10
pd-α− PI
standard
1  2   3   4   5  6  7   8   9   10Microbial Cell Factories 2007, 6:34 http://www.microbialcellfactories.com/content/6/1/34
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glycosylated r-α1-PI from the A. niger supernatant (solid
trace) is relatively stable during at least 12 hours.
4.2. Evaluation of molecular mass
The molecular mass sizes of r-α1-PI's were evaluated by
SDS-PAGE and Western blot analysis, using pd-α1-PI and
its deglycosylated version as the references (Fig. 4). In
addition, we performed mass-spectrometric analysis of
the proteins using MALDI-MS in the conditions estab-
lished earlier [22]. α1-PI is a heterogeneous protein due to
intrinsic carbohydrate diversity and some differences in
the polypeptide part [23-26]. Therefore, in the MALDI-MS
spectra the molecular ion and the related ions are repre-
sented by its ion distribution clusters, and the molecular
mass values are assigned by the major ion peak at which
the cluster is centered. The molecular weight of the stand-
ard pd-α1-PI (spectra not shown) is determined by the
observed molecular ion [M+H]+ at 50,300 Da (Table 1),
which is in agreement with its half-mass ion [M/2+H]+
detected at 25,150 Da. Mass spectrum of r-α1-PI from A.
niger shows the molecular ion cluster centered at 50,130
Da, which is close to that of plasma α1-PI standard. There-
fore, these results allow for more accurate molecular mass
values and suggest that there is no "hyperglycosylation" in
case of r-α1-PI secreted from A. niger. Enzymatically degly-
cosylated pd-α1-PI showed the main molecular ion at
44,210 Da, therefore, serving as an additional non-glyco-
sylated reference.
4.3. Activity of r-α1-PI
Inhibitory activity of the recombinant α1-PI secreted into
the supernatant was evaluated against porcine pancreatic
trypsin, using pd-α1-PI as a standard (assigned as 100%,
Table 1). The α1-PI assay samples were adjusted to the
same initial concentration and subjected to the same dilu-
tions on the plate. Basal (low) response of the supernatant
from the growth of D15#26 transformed with PyrG only
was subtracted. Activity of the r-α1-PI from A. niger was
not less than 75% of the standard (e.g., to inhibit 0.7
μmole active PPT about 0.92 μmole of r-α1-PI was
Table 1: Activity of r-α1-PI from E. coli and A. niger and evaluation of molecular weight of recombinant and plasma-derived species 
determined by MALDI-MS
Protein Activitya (%) Molecular massb
pd-α1-PI (standard) 100 50,300
degly-pd-α1-PI n.a.c 44,210
r-α1-PI/E. coli 35d 45,000e
r-α1-PI/A. niger 76f,g 50,100
aThe calculations were based on comparison with pdtαxtPI as a standard (100%) and using normalized equal concentrations of r-α1-PI samples as 
determined by ELISA; bmolecular weight is shown as a an average value measured for 2 samples; c not available; pd-α1-PI was enzymatically 
deglycosylated under denaturing conditions; d as measured for His-tagged r-α1-PI within 1.5 h after elution from the TALON beads; e as estimated 
by amino acid sequence for α1-PI without glycans; f shown for A. niger supernatant after Amicon 10 K filtration procedure; g the standard deviation 
of our potency assay is ± 15%.
Evaluation of stability of r-α1-PI from A. niger (solid trace) and from E. coli (dashed trace) by SE-HPLC Figure 5
Evaluation of stability of r-α1-PI from A. niger (solid trace) and from E. coli (dashed trace) by SE-HPLC. The fractions of r-α1-PI 
were collected by HPLC, kept on ice and re-injected. The gray dashed trace reflects polymerization of r-α1-PI from E. coli as 
shown 1.5 h later after elution, while no aggregation was observed for r-α1-PI from A. niger for ~12 hours; all analytes were 
stored at 4°C.Microbial Cell Factories 2007, 6:34 http://www.microbialcellfactories.com/content/6/1/34
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required). This activity was significantly higher than that
of r-α1-PI from E. coli (~35%). The latter correlates well
with the fact that non-glycosylated r-α1-PI from E. coli
tends to aggregate rapidly with subsequent loss of activity.
Discussion
In this paper we demonstrate that it is possibile to express
the human gene for α1-PI in the filamentous fungus A.
niger as a secreted glycosylated protein with stability that
is significantly improved in comparison with non-glyco-
sylated recombinant protein from E. coli. The secreted r-
α1-PI was characterized in comparison with pd-α1-PI and
its enzymatically deglycosylated version (de-pd-α1-PI)
used as the "in-house" standards, as well as with non-glyc-
osylated r-α1-PI produced in E. coli [27].
A. niger strains have been already used as hosts for the pro-
duction of other serine proteinase inhibitors. Mikosch et
al. reported on the secretion of active human mucus pro-
teinase inhibitor (antileukoproteinase), which is a 11.7
kDa non-glycosylated single chain protein stabilized by
eight disulfide bonds [16]. Later, MacKenzie et al.
reported on an aberrant processing of bovine pancreatic
trypsin inhibitor (known as aprotinin, a small polypep-
tide of 58 amino acid residues) secreted by A. niger [20].
However, to the best of our knowledge, our work shows
for the first time that human α1-PI, a complex glycopro-
tein of medium size (394 amino acid residues, ~50.3 kDa)
and of significant therapeutic value, can be successfully
produced in this system.
The expression of α1-PI in A. niger was designed to obtain
the recombinant inhibitor in the secreted glycosylated
form with enhanced yield. This was successfully achieved
by fusion of the α1-PI coding sequence downstream of the
glucoamylase truncated gene (glaAG2), under transcrip-
tional control of the constitutively expressed glyceralde-
hydes-3-phosphate dehydrogenase (gpdA) promoter,
according to the earlier established strategy [14-16]. The
efficiency of protein production was evaluated by the level
of expression by direct determination of the secreted r-α1-
PI in the supernatant during growth.
To minimize possible interactions of native fungal pro-
teases with the target recombinant inhibitor during
growth, the following changes were implemented: (a) a
protease-deficient mutant D15#26 was used for transfor-
mation (instead of AB4-1), and (b) the pH of the superna-
tants was maintained above 7.0. Screening for the target
protein was routinely assayed by ELISA, in a protocol
recently developed by us for this purpose [21]. However,
given the subtle nature of α1-PI and the challenge of pro-
ducing this medium size inhibitor in its biologically active
form, standard SDS-PAGE/Western blot analysis was also
conducted to visualize evidence for degradation peptides.
As an analytical tool, ELISA was utilized to quantify r-α1-
PI's production under various growth conditions. Maxi-
mum yields of r-α1-PI achieved in shake-flask cultures
were at 12 mg/L, after 96 hours of batch culture growth,
which is comparable with those reported for other mam-
malian proteins (10 mg/L) that were obtained in Aspergil-
lus  strains [16,17,28]. Although these yields of r-α1-PI
appear to be lower than the yields we achieved in E. coli
(20 mg/L and 38 mg/L in raw extracts before purification),
the protein obtained from A. niger is significantly more
stable than the non-glycosylated α1-PI versions from E.
coli, as evaluated by SE-HPLC.
Furthermore, inhibitory activity of r-α1-PI from A. niger is
significantly higher than that of non-glycosylated r-α1-PI
version from E. coli, which tends to aggregate more rap-
idly, thereby losing its inhibitory activity. This is consist-
ent with the previously reported data on activity and
stability of r-α1-PI's that were produced in other host sys-
tems [8], thus confirming that low stability results in
lower potency.
As was reported earlier for bovine pancreatic trypsin
inhibitor [20], the possibility for aberrant processing of
the fusion protein by KEX2-like endoprotease may result
in a mixture of target proteins differing at the N-terminus.
Although this possibility was not evaluated for r-α1-PI
obtained from shake-flask cultures, the secreted r-α1-PI
had high inhibitory activity (not less than 75%) in this
system, suggesting that r-α1-PI was mostly processed cor-
rectly. Although a higher yield was mentioned for r-α1-PI
produced in a fermentor [8], it related to a total r-α1-PI
that contained certain amounts of latent (inactive) and
digested α1-PI species. The optimization for a semi-large
scale production of r-α1-PI in a fermentor with all param-
eters controlled is currently under development [29].
As the secreted protein, r-α1-PI is glycosylated, and the
SDS-PAGE and Western blot demonstrate that the electro-
phoretic mobility of r-α1-PI from A. niger is comparable
with that of pd-α1-PI standard. Together with the activity
results and SE-HPLC data, it suggests a correct cleavage by
KEX2-like site and an appropriate folding of the secreted
protein. MALDI-MS data provide additional proof that the
average molecular mass of the recombinant protein
(~50,100 Da) is close to that observed for pd-α1-PI
(50,300 Da), and therefore, the sizes of glycans in both
are comparable. Although the results of testing with
PNGase F suggest that glycosylation is predominantly of
N-type, more detailed glycan characterization could be of
interest in view of the comprehensive glyco-proteomic
analysis recently performed by Kolarich et al. [25,26] for
native human α1-PI.Microbial Cell Factories 2007, 6:34 http://www.microbialcellfactories.com/content/6/1/34
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Conclusion
As a part of our multi-step investigation of α1-PI, we have
successfully expressed the human gene for α1-PI in the fil-
amentous fungus Aspergillus niger, as a fusion protein with
glucoamylase G2, a strongly expressed secreted leader pro-
tein, separated by a processing peptide sequence to allow
in vivo cleavage. SDS-PAGE, Western blot, ELISA and
inhibitory activity assays enabled us to select the trans-
formant(s) that were capable of secreting biologically
active glycosylated r-α1-PI with improved stability and
with yields of up to 12 mg/L. MALDI-MS analysis further
confirmed that molecular mass of the r-α1-PI was similar
to that of native plasma protein, thus suggesting that there
was no "hyperglycosylation" from the host. Taken
together, the results of our shake-flask experiments sug-
gest the feasibility of this system for further development
of r-α1-PI, a protein of our particular therapeutic interest.
Methods
1. α1-PI references, reagents and solutions
α1-PI from CalBiochem (Darmstadt, Germany) was used
as an "in-house" α1-PI standard which was qualified as
earlier described [21]. The concentrations of the purified
α1-PI preparations were determined spectrophotometri-
cally using a coefficient of extinction A280
0.1% 0.433 [30].
Deglycosylated and non-glycosylated α1-PI reference sam-
ples were prepared as described below. Bovine serum
albumin, trypsin from porcine pancrease, p-nitrophenyl
p'-guanidino-benzoate hydrochloride (NPGB), N-ben-
zoyl-L-arginine p-nitroanalide hydrochloride (BApNA), 2-
mercaptoethanol, anhydrous dibasic sodium phosphate,
3,3',5,5'-tetra-methylbenzidine (TMB) liquid substrate
system for membrane and TMB for ELISA, isopropyl β-D-
1-thiogalacto-pyranoside (IPTG), PNGase F and sinapinic
acid were from Sigma Chemical Co. (St. Louis, MO). Hex-
afluoroisopropanol was from Brand-Nu Laboratories
(Meriden, CT). Cellulase was from Interspex Product (San
Mateo, CA). Phosphate buffered saline (D-PBS) without
Ca & Mg was from Quality Biological, Inc., (Gaithersburg,
MD). Simply BlueTM SafeStain and SeeBlue Plus2® Pre-
Stained Standard were from Invitrogen (Carlsbad, CA).
All other chemicals were ACS reagent grade from Fisher
Scientific (Pittsburgh, PA). Antibodies for Western blot:
goat anti-human α1-PI affinity purified and rabbit anti-
goat alkaline phosphatase (AP) conjugate were from Jack-
son ImmunoResearch Laboratories (West Grove, PA). AP
Conjugate Substrate Kit to visualize the alkaline phos-
phatase in Western blot was from Bio-Rad Laboratories
(Hercules, CA). Antibody for ELISA: rabbit anti-human
α1-PI (capture antibody) from Sigma Chemical Co. (St.
Louis, MO) and sheep anti-human α1-PI-HRP (antibody-
enzyme conjugate) from BioDesign International (Saco,
ME).
2. Strains
Aspergillus niger (pyrG-) strains AB4-1 (parental) and
D15#26, a protease-deficient, non-acidifying mutant [31]
from TNO were used for transformation and production
of glycosylated r-α1-PI. E. coli strain TOP10 used for con-
struction and propagation of vectors was from Invitrogen
Co. (Carlsbad, CA). E. coli strain JM109 used for cDNA
preparation was from Promega Co. (Madison, WI).
3. Culture conditions
For selection of the A. niger transformants, the following
selective solid minimal uridine-deficient medium was
used containing (per 1 liter): 5.95 g NaNO3, 0.52 g KCl,
1.5 g KH2PO4, 0.24 g MgSO4, 1% (wt/vol) glucose, and
trace elements (1,000 × stock: 12.27 g ZnSO4, 3.15 g
MnCl2, 5.0 g FeSO4× 7H2O,0.92 g CoCl2, 1.02 g CuSO4,
1.28 gNa2MoO4, 50.8 g EDTA).
The biomass for protoplasting and transformation was
obtained by growing in the complete media that con-
tained (per 1 liter): 6 g NaNO3, 0.52 g KCl, 0.68 g
KH2PO4, 1.045 g K2HPO4, 2.77 g MgSO4 × 7 H2O, 1 g
yeast extract, 1 g casamino acids, 10 g glucose, 1 ml vita-
mins solution (per 100 ml: 0.01 g pyridoxine-HCl, 0.015
g thiamine-HCl, 0.075 g p-aminobenzoic acid, 0.25 g nic-
otinic acid, 0.25 g riboflavin, 2.0 g choline-HCl, 0.005 g
biotin), 1 ml trace solution (per 100 ml: 2.2 g ZnSO4, 1.1
g H3BO3, 0.5 g MnCl2 × 4 H2O, 0.5 g FeSO4 × 7 H2O, 0.16
g CoCl2 × 6 H2O, 0.16 g CuSO4, 0.11 g (NH4)2MoO4, 6.5
g EDTA tetrasodium salt) supplemented with 10 mM of
uridine.
4. DNA and plasmids
The gene for human α1-PI was kindly provided by Dr.
Sanio Woo (Mount Sinai, NY, NY). The pAN56-1 vector
and PyrG selection plasmid were from Dyadic Nederland
BV.
5. Construction of expression plasmid
The expression vector pAN56-1/α1-PI (Figure 1) was con-
structed using established molecular methods protocols
[32]. A full length 1230 bp cDNA encoding the mature
human α1-PI (GenBank Accession # K01396) was gener-
ated by PCR flanked by BstB1 restriction sites and linked
with nucleotide sequence encoding a dibasic processing
site (N-V-I-S-K-R). The following primers were used: (1) 5'
TTCGAATGTGATATCCAAGCGCGGAGATCCCCAG-
GGAGATGCTGCCC containing a processing sequence 
(underlined), and (2) 3' TTCGAATTATTTTTGGGTGGGAT-
TCACCACTTTTCCCATGAAGAGGGGTGGG. PCR was per-
formed using Model PTC-200 of Peltier Thermal Cycler (MJ
Research, Inc.). The PCR fragment was then ligated into the
plasmid pCR2.1 TOPO (Invitrogen Co., Carlsbad, CA) and
the sequence of the amplification product was confirmed
by sequencing at the CBER FDA core facilities. Excising theMicrobial Cell Factories 2007, 6:34 http://www.microbialcellfactories.com/content/6/1/34
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fragment by BstB1 allows the subcloning into the NarI
digested expression vector pAN56-1 (from TNO, Gen-
Bank Accession # Z32700) to generate pAN56-1/α1-PI.
The cloning resulted in expression cassette that contained
the constitutively expressed glyceraldehydes-3-phosphate
dehydrogenase promoter (PgpdA), gene for mature human
α1-PI fused to the coding region of glucoamylase trun-
cated gene (GLA) linked by the processing site, followed
by the trpC terminator (TtrpC).
6. Transformation and selection of A. niger transformants
The A. niger strain D15#26 was grown in minimal media
(above) for 16 h at 30°C with shaking at 150 rpm. The
protoplasts preparation and transformation was followed
as described in [33] with the exception of using 5 mg of
cellulase per mL of wet mycelia instead of NovoZym 234.
The protoplasts were co-transformed with the expression
vector pAN56-1/α1-PI and PyrG selection plasmid. PyrG
transformants were selected on plates of solid minimal
media without uridine, prepared with 15 g/L Oxoid agar.
The plates were incubated at 30°C for 2 days until fungal
colonies became visible. Large colonies were selected and
subsequently transferred onto new plates prior to screen-
ing for α1-PI production in minimal liquid media.
7. Screening for α1-PI producers by SDS-PAGE and 
Western blot
The selected PyrG transformants were screened for the
appearance of r-α1-PI in the supernatants during growth
(200 mL per 1000 ml flask at 28°C on rotary shaker at 150
rpm and incubated for 5 days; pH was maintained above
7.0 by using 2 M NaOH solution). The aliquots of the
supernatants were collected during the 5 days growth and
analyzed for the presence of secreted r-α1-PI by SDS-PAGE
and Western blot analysis using pre-cast 7.5% and 4–20%
Tris/Gly mini-gels under reducing conditions. Simply
BlueTM SafeStain was used for staining, and SeeBlue Plus2®
Pre-Stained Standard served as the protein ladder. Goat
anti-human α1-PI affinity purified and rabbit anti-goat
alkaline phosphatase (AP) conjugate followed by detec-
tion with AP Conjugate Substrate Kit were used in the
Western blot to visualize the protein. Based on the screen-
ing, the best transformant was selected for further studies.
8. Quantification of r-α1-PI by ELISA
Quantification of r-α1-PI in raw biological samples was
performed as in [21]. The samples were assayed in tripli-
cate. Spiking with the supernatant aliquots adjusted to pH
7.3 and 8.4 have been conducted similarly. The blank
supernatant from growth of A. niger transformed with
PyrG plasmid only, was used as a matrix to confirm the
specificity of the antigenic determination.
9. Evaluation of α1-PI proteolytic digestion by fungal 
proteases
To evaluate for possible proteolytic degradation of r-α1-PI
during growth, the standard pd-α1-PI was diluted to 5.175
mg/mL by adding Tris buffer or A. niger supernatant from
the strain D15#26. The samples (in Tris and in superna-
tant) were incubated at 4°C and at RT for overnight (O/
N), and evaluated by ELISA according to the protocol ear-
lier described [21].
10. SE-HPLC
SE-HPLC analysis was carried out on the System Gold®
HPLC (Beckmann Corp.) controlled by 32 Karat Work sta-
tion software. The stationary phase: two TosoHaas TSK-
3000SWXL columns (5 μm, 7.8 mm × 30 cm) connected in
series and an SWXL guard column. The mobile phase: PBS
buffer, pH 7.4. The flow rate: 1 mL/min. Detection:
absorbance at 280 and 215 nm.
11. Activity assay
The inhibitory activities of r-α1-PI's produced in A. niger
and in E. coli were evaluated against trypsin from porcine
pancrease. Titration of trypsin active sites was performed
using NPGB as an active-site titrant according to the estab-
lished procedure [34]. Our plate-based version of this
assay reproducibly showed 76% of the active sites in the
porcine pancreatic trypsin. Determination of the inhibi-
tory activity of α1-PI is based on measuring the residual
assay protease activity after trypsin interaction with vari-
ous amounts of α1-PI. The inhibitory activity of r-α1-PI
was determined in comparison with an in-house standard
(100%) and using BApNA as a chromogenic substrate.
The residual trypsin activity was measured by monitoring
the absorbance of the released p-nitroanilide at 405 nm
(molar extinction coefficient of 10,500 M-1cm-1).
The samples of r-α1-PIs from A. niger and E. coli were pre-
pared for assaying inhibitory activity as follows. (a) r-α1-
PI from E. coli. Soluble cytosolic protein fractions from E.
coli  biomass were subjected to purification on TALON
beads, the eluted fractions containing r-α1-PI were col-
lected and concentrated using Amicon (10 K) filtration at
13,000 rpm; the concentrate was analyzed by SE-HPLC,
and the fraction eluted at 21 min was collected and placed
on ice. The r-α1-PI concentration was determined spectro-
photo-metrically, and its activity was immediately
assayed. (b) Inhibitory activity of r-α1-PI from A. niger
transformants was evaluated as follows. The supernatants
(pH 7.0) were concentrated and desalted by aid of filtra-
tion on Amicon 10 K and kept on ice before use the same
day. Samples in 1 mL aliquots were mixed with equal vol-
ume of Tris buffer, pH 8.4, and cleared by centrifugation
at 24,000 rpm for ~5 min. The r-α1-PI concentration was
determined by ELISA as described above. Trypsin solution
in Tris buffer served as a control protease sample. AfterMicrobial Cell Factories 2007, 6:34 http://www.microbialcellfactories.com/content/6/1/34
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mixing with the samples containing standard α1-PI and r-
α1-PI samples, the mixtures were incubated for 15 min at
RT. After adding 100 μL of the substrate solution, simulta-
neously by using a multi-channel pipette, the residual
trypsin activity was immediately monitored as end point
kinetics at 405 nm on THERMOmax™ microplate reader
(Molecular Devices Co., Menlo Park, CA).
Trypsin active site titration and the inhibitory assay were
performed in duplicate at 25°C in Tris buffer (pH 8.4).
Back calculations for activities of r-α1-PIs in the original
samples were performed using the corresponding dilution
factors.
12. MALDI-MS
A linear time-of-flight instrument with delayed extraction
(Voyager-DE, Applied Biosystems, Framingham, MA) was
used. Mass calibration was performed using bovine serum
albumin (66,500 Da) as an internal standard. The average
of 50–200 laser shots was used for recording the mass
spectra within the acquisition mass range of 15,000 –
80,000 Da. The samples were prepared as described in
[22] with minor changes as following. The samples (1 μL
of supernatants containing α1-PI or standard pd-α1-PI)
were loaded onto a gold-plated sample plate and allowed
to air dry. The matrix solution was prepared by mixing 12
μg of sinapinic acid with 300 μL of 0.1% trifluoroacetic
acid/acetonitrile (1:1, v/v). After spinning down at 5,000
rpm, 1 μL of the resulting solution was loaded on the top
of each spot of the sample and allowed to air dry prior to
measurement of the mass spectra.
13. Deglycosylated α1-PI reference
De-pd-α1-PI was obtained from pd-α1-PI by enzymatic
deglycosylation using PNGase F according to the proce-
dure described elsewhere [35]. The de-pd-α1-PI was
diluted with water to concentration 0.2 μg/μL followed by
1:1 (v/v) dilution with Laemmli buffer, boiled for 3 min
and stored (aliquoted) at -20°C until use.
14. Non-glycosylated r-α1-PI reference produced in E. coli
Expression of the human gene for α1-PI in E. coli special
strain BL21(DE3)pLysS (Novagen) was performed as a 9-
His-tagged protein as reported earlier [27]. Briefly, the
human gene for α1-PI was cloned into the pET-19b vector.
The expression vector ET-19b, PCR II TOPO vector, TOPO
TA Cloning Kit and the restriction enzymes were from
(Novagen). After transformation, the host cells
Rosetta(DE3)pLysS containing the pET-19b/α1-PI con-
struct were grown overnight at 37°C and 250 rpm in LB
media containing Ampicillin (100 μg/mL) to a density of
0.8–0.9 OD read at 600 nm (OD600). After inoculation
(1:100), a culture of LB-medium supplemented with
ampicillin (100 μg/mL) was grown (37°C, at 250 rpm) to
an OD600 of 0.5, and the expression was induced by add-
ing 1.0 mM IPTG. The growth was continued for another
3 h (37°C, 250 rpm) to OD600 of 1.1–1.3. The cells were
harvested by centrifugation (15 min, 5,000 rpm, 4°C),
and washed twice with PBS buffer, pH 7.4, by resuspend-
ing and centrifugation. The washed cells were lysed, and
the soluble fraction was used for the r-α1-PI purification
on TALON beads. (Blank culture with pET-19B vector
without α1-PI gene was performed in a similar manner,
and the supernatant served as a control to assure the spe-
cificity of α1-PI quantification by ELISA and potency
measurements.)
List of abbreviations
α1-PI, α1- proteinase inhibitor; r-α1-PI, recombinant α1-
PI; A. niger, Aspergillus niger; AP, alkaline phosphatase;
BApNA, N-benzoyl-L-arginine p-nitroanalide hydrochlo-
ride; de-pd-α1-PI, deglycosylated pd-α1-PI; ELISA,
Enzyme-Linked ImmunoSorbent Assay; glaA, glucoamy-
lase A; HRP, horse radish peroxidase; IPTG, isopropyl β-
D-1-thiogalacto-pyranoside; MALDI-MS, matrix-assisted
laser desorption/ionization mass spectrometry; NPGB, p-
nitrophenyl  p'-guanidino-benzoate hydrochloride; pd-,
plasma-derived; RT, room temperature; SDS-PAGE,
sodium dodecyl sulphate polyacrylamide gel electro-
phoresis; SE-HPLC, size-exclusion high-performance liq-
uid chromatography; serpin, serine protease inhibitor; U,
uridine.
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